Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SC262 |
Synonyms | |
Therapy Description |
Limited information is currently available on SC262, a putative chimeric antigen receptor (CAR) T-cell therapy targeting CD22 (May 2024). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SC262 | SC-262|SC 262 | CD22 Immune Cell Therapy 15 | Limited information is currently available on SC262, a putative chimeric antigen receptor (CAR) T-cell therapy targeting CD22 (May 2024). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06285422 | Phase I | Cyclophosphamide + Fludarabine SC262 | Study Evaluating SC262 in Subjects With r/r B-cell Malignancies (VIVID) | Recruiting | USA | 0 |